A detailed history of Deutsche Bank Ag\ transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 282,062 shares of LRMR stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282,062
Previous 274,576 2.73%
Holding current value
$1.08 Million
Previous $1.99 Million 7.19%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.3 - $10.68 $47,161 - $79,950
7,486 Added 2.73%
282,062 $1.85 Million
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $16,787 - $26,228
2,652 Added 0.98%
274,576 $1.99 Million
Q1 2024

May 15, 2024

SELL
$4.2 - $13.28 $1,885 - $5,962
-449 Reduced 0.16%
271,924 $2.06 Million
Q4 2023

Feb 14, 2024

BUY
$2.35 - $4.71 $640,076 - $1.28 Million
272,373 New
272,373 $1.24 Million
Q1 2023

May 15, 2023

BUY
$4.0 - $6.68 $1.02 Million - $1.71 Million
255,593 New
255,593 $1.16 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $166M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.